Pre-made Polatuzumab benchmark antibody ( Whole mAb ADC, anti-CD79B therapeutic antibody, Anti-AGM6/B29/IGB Antibody) for drug discovery and mechanism of action (MOA) research
Cat No.: GMP-Bios-ab-449
Pre-Made Polatuzumab biosimilar, Whole mAb ADC, Anti-CD79B Antibody: Anti-AGM6/B29/IGB therapeutic antibody is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for biological drug disovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.
Polatuzumab vedotin contains a monoclonal antibody that binds to a protein called CD79B, which is found on B cells (a type of white blood cell) and some lymphoma cells. It also contains an anticancer drug, which may help kill cancer cells. Polatuzumab vedotin is a type of antibody-drug conjugate. Also called Polivy.
* GeneMedi provides NON-PROFIT PRICE to support Academic research. Please click inquiry for product quotation. → Inquiry
|Catalog No.||Package||Price(In USD)||Qty (Quantity)||Sum(In USD)|
|Products Name (INN Index)||Pre-Made Polatuzumab biosimilar, Whole mAb ADC, Anti-CD79B Antibody: Anti-AGM6/B29/IGB therapeutic antibody|
|Format||Whole mAb ADC|
|Highest_Clin_Trial (Jan '20)||Approved|
|100% SI Structure||None|
|99% SI Structure||None|
|95-98% SI Structure||None|
|Conditions Approved||Diffuse large B cell lymphoma|
|Conditions Active||Non-Hodgkin's lymphoma;Follicular lymphoma|
|Conditions Discontinued||Chronic lymphocytic leukaemia|